Parker-Hannifin Total Cost of Revenue increased by 7.0% to $3.47B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.8%, from $3.13B to $3.47B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 4.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.83B | $2.71B | $2.76B | $2.93B | $2.98B | $2.80B | $3.24B | $3.34B | $3.26B | $3.10B | $3.10B | $3.28B | $3.32B | $3.10B | $3.02B | $3.13B | $3.29B | $3.18B | $3.24B | $3.47B |
| QoQ Change | — | -4.2% | +1.9% | +5.9% | +1.8% | -6.2% | +15.8% | +3.2% | -2.3% | -5.1% | +0.1% | +5.7% | +1.3% | -6.8% | -2.4% | +3.6% | +5.0% | -3.3% | +2.1% | +7.0% |
| YoY Change | — | — | — | — | +5.2% | +3.0% | +17.1% | +14.1% | +9.5% | +10.8% | -4.2% | -1.8% | +1.8% | +0.0% | -2.6% | -4.6% | -1.1% | +2.6% | +7.3% | +10.8% |